Description
SEBI has completed Recovery Certificate No. 4355 of 2021 issued against Venmax Drugs and Pharmaceuticals Limited (PAN: AAACY1073C), signifying successful conclusion of the recovery proceedings.
Summary
SEBI has formally completed Recovery Certificate No. 4355 of 2021 issued against Venmax Drugs and Pharmaceuticals Limited (PAN: AAACY1073C). This order marks the conclusion of the recovery proceedings initiated against the company, indicating that the dues specified in the recovery certificate have been satisfied or the certificate has otherwise been resolved.
Key Points
- Recovery Certificate No. 4355 of 2021 against Venmax Drugs and Pharmaceuticals Limited (PAN: AAACY1073C) has been completed.
- The completion order was issued in March 2026, approximately five years after the original certificate was issued in 2021.
- This is an enforcement/recovery action specific to the named entity and does not represent a new regulatory directive.
Regulatory Changes
No new regulatory changes are introduced by this order. It is an administrative completion of an existing recovery proceeding.
Compliance Requirements
No new compliance requirements for market participants. This order is specific to Venmax Drugs and Pharmaceuticals Limited and pertains to the closure of their recovery obligations under Certificate No. 4355 of 2021.
Important Dates
- Recovery Certificate No. 4355 originally issued: 2021
- Completion Order issued: March 2026
Impact Assessment
Minimal market impact. This is a routine administrative closure of a recovery proceeding against a single defaulting entity. It does not affect broader market participants, listed securities, or trading operations. Investors in Venmax Drugs and Pharmaceuticals Limited should note the conclusion of SEBI’s recovery action against the company.
Impact Justification
Administrative closure of a recovery certificate against a single defaulting entity. No market-wide regulatory changes or new compliance requirements introduced. Impact is limited to the specific defaulter.